AR023807A1 - Un agente para tratar el ojo seco y el uso de un compuesto macrolido para preparar composiciones farmaceuticas para el tratamiento del ojo seco - Google Patents

Un agente para tratar el ojo seco y el uso de un compuesto macrolido para preparar composiciones farmaceuticas para el tratamiento del ojo seco

Info

Publication number
AR023807A1
AR023807A1 ARP000102060A ARP000102060A AR023807A1 AR 023807 A1 AR023807 A1 AR 023807A1 AR P000102060 A ARP000102060 A AR P000102060A AR P000102060 A ARP000102060 A AR P000102060A AR 023807 A1 AR023807 A1 AR 023807A1
Authority
AR
Argentina
Prior art keywords
dry eye
agent
pharmaceutical compositions
compound
macrolid
Prior art date
Application number
ARP000102060A
Other languages
English (en)
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452015&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR023807(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of AR023807A1 publication Critical patent/AR023807A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente provee un agente para tratar el ojo seco, que contiene un compuesto macrolido tal como el FK 506, de formula (1). También se describe el uso dedichos macrolidos para la preparacion de las composiciones farmacéuticas destinadas al tratamiento del ojo seco.
ARP000102060A 1999-04-30 2000-04-28 Un agente para tratar el ojo seco y el uso de un compuesto macrolido para preparar composiciones farmaceuticas para el tratamiento del ojo seco AR023807A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13200999P 1999-04-30 1999-04-30

Publications (1)

Publication Number Publication Date
AR023807A1 true AR023807A1 (es) 2002-09-04

Family

ID=22452015

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102060A AR023807A1 (es) 1999-04-30 2000-04-28 Un agente para tratar el ojo seco y el uso de un compuesto macrolido para preparar composiciones farmaceuticas para el tratamiento del ojo seco

Country Status (23)

Country Link
EP (1) EP1173177B2 (es)
JP (2) JP5036934B2 (es)
KR (1) KR20020015316A (es)
CN (1) CN1190194C (es)
AR (1) AR023807A1 (es)
AT (1) ATE281167T1 (es)
AU (1) AU777915B2 (es)
BR (1) BR0011225A (es)
CA (1) CA2372448A1 (es)
CZ (1) CZ20013769A3 (es)
DE (1) DE60015516T2 (es)
ES (1) ES2232439T3 (es)
HK (2) HK1043321B (es)
HU (1) HUP0200864A3 (es)
IL (1) IL146162A0 (es)
MX (1) MXPA01010988A (es)
NO (1) NO20015288D0 (es)
NZ (1) NZ515339A (es)
PT (1) PT1173177E (es)
TR (1) TR200103119T2 (es)
TW (1) TWI230066B (es)
WO (1) WO2000066122A1 (es)
ZA (1) ZA200108905B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2372448A1 (en) * 1999-04-30 2000-11-09 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
CA2452372A1 (en) 2001-07-06 2003-01-16 Sucampo Ag Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
AR038628A1 (es) * 2002-03-04 2005-01-19 Novartis Ag Composicion oftalmica
US20050239813A1 (en) * 2002-08-09 2005-10-27 Sucampo Pharmaceuticals Inc. Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
WO2004062669A1 (en) * 2003-01-16 2004-07-29 Sucampo Ag Use of a macrolide compound for treating dry eye
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
WO2005032534A1 (ja) 2003-10-06 2005-04-14 Ophtecs Corporation 涙液異常の治療のための眼科用組成物
US20060258698A1 (en) 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
EP1904056B1 (en) 2005-07-18 2009-04-29 Minu, L.L.C. Use of a macrolide to restore corneal sensation
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20200147055A1 (en) * 2017-05-30 2020-05-14 Eximore Ltd. Compositions and methods for treating dry eye syndrome delivering antibiotic macrolide
WO2019060696A1 (en) 2017-09-25 2019-03-28 Surface Pharmaceuticals, Inc. OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0406791T3 (da) * 1989-07-05 1995-03-27 Fujisawa Pharmaceutical Co Vandigt flydende præparat til ekstern anvendelse
ATE198708T1 (de) * 1991-04-26 2001-02-15 Fujisawa Pharmaceutical Co Verwendung von makrolid-verbindungen gegen augenerkrankungen
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
JP2002509555A (ja) * 1998-04-06 2002-03-26 藤沢薬品工業株式会社 新規用途
ID29262A (id) * 1998-04-27 2001-08-16 Fujisawa Pharmaceutical Co Komposisi farmasi
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
CA2372448A1 (en) * 1999-04-30 2000-11-09 Sucampo Ag Use of macrolide compounds for the treatment of dry eye

Also Published As

Publication number Publication date
NO20015288L (no) 2001-10-29
BR0011225A (pt) 2002-03-19
TWI230066B (en) 2005-04-01
AU4142900A (en) 2000-11-17
ES2232439T3 (es) 2005-06-01
NZ515339A (en) 2004-02-27
JP5036934B2 (ja) 2012-09-26
CA2372448A1 (en) 2000-11-09
IL146162A0 (en) 2002-07-25
CN1190194C (zh) 2005-02-23
HUP0200864A2 (hu) 2002-07-29
CZ20013769A3 (cs) 2002-03-13
HUP0200864A3 (en) 2004-07-28
ATE281167T1 (de) 2004-11-15
KR20020015316A (ko) 2002-02-27
EP1173177A1 (en) 2002-01-23
JP2002543132A (ja) 2002-12-17
MXPA01010988A (es) 2004-04-21
ZA200108905B (en) 2002-12-24
EP1173177B2 (en) 2014-03-05
DE60015516D1 (de) 2004-12-09
NO20015288D0 (no) 2001-10-29
HK1043321A1 (en) 2002-09-13
HK1046099A1 (zh) 2002-12-27
HK1043321B (zh) 2005-07-15
DE60015516T2 (de) 2005-12-01
WO2000066122A1 (en) 2000-11-09
EP1173177B1 (en) 2004-11-03
JP2012116857A (ja) 2012-06-21
TR200103119T2 (tr) 2002-04-22
PT1173177E (pt) 2005-03-31
AU777915B2 (en) 2004-11-04
CN1353608A (zh) 2002-06-12

Similar Documents

Publication Publication Date Title
AR023807A1 (es) Un agente para tratar el ojo seco y el uso de un compuesto macrolido para preparar composiciones farmaceuticas para el tratamiento del ojo seco
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
BR0215052A (pt) Composições acaricidas e métodos
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
AR006867A1 (es) Composición topica para la piel que comprende un compuesto oxa-diácido, su uso para preparar un medicamento para tratar condiciones de la piel y métodos cosméticos no terapéuticos para el pulido de la piel y para suavizar el cabello que aplican dicho compuesto.
BR9812122A (pt) Combinação de inibidor da tirosina quinase e castração quìmica para tratar câncer da próstata
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0200782A (pt) Compostos para o tratamento da isquemia
ES2065471T3 (es) Composiciones acuosas antibacterianas que comprenden un tensoactivo y bacteriofagos.
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
ES2044912T3 (es) Composiciones farmaceuticas dotadas de actividad secuestrante para los acidos biliares, conteniendo colestiramina como principio activo, y procedimiento para su preparacion.
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
PT1056454E (pt) Utilizacao de compostos macrolido para o tratamento do glaucoma
AR003427A1 (es) Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas.
ES2178036T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que le contienen.
ES2243579T3 (es) Derivados de pirazolopirideno.
PA8485601A1 (es) Azalidas de 13 miembros y su uso como agentes antibioticos.
BR9507730A (pt) Uso de formulações em gel como composições de tratamento
AR007021A1 (es) Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos
ES2194535T3 (es) 4-trifluorometil-3-oxazolilpiridinas, procedimiento para su preparacion, agentes que las contien y su uso como agente parala lucha contra organismos dañinos.
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
BR9911559A (pt) Processo para a preparação de um composto, composto, processo para o tratamento de tumores resistentes a medicamento múltiplo, uso de um composto, e, agente e composição para tratar tumores resistentes a medicamento múltiplo.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal